These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17707127)

  • 1. Points to consider emerging from a mini-workshop on cardiac safety: assessing torsades de pointes liability.
    Bass A; Valentin JP; Fossa AA; Volders PG
    J Pharmacol Toxicol Methods; 2007; 56(2):91-4. PubMed ID: 17707127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.
    Bass AS; Darpo B; Breidenbach A; Bruse K; Feldman HS; Garnes D; Hammond T; Haverkamp W; January C; Koerner J; Lawrence C; Leishman D; Roden D; Valentin JP; Vos MA; Zhou YY; Karluss T; Sager P
    Br J Pharmacol; 2008 Aug; 154(7):1491-501. PubMed ID: 18663380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving towards better predictors of drug-induced torsades de pointes.
    Bass AS; Darpo B; Valentin JP; Sager P; Thomas K
    Br J Pharmacol; 2008 Aug; 154(7):1550-3. PubMed ID: 18574462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving towards better predictors of drug-induced Torsade de Pointes. 2-3 November 2005, Crystal City, Virginia, USA.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2006 Mar; 5(2):335-40. PubMed ID: 16503753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Gintant G; Turner JR; Pettit S; Stockbridge N
    Am Heart J; 2014 Mar; 167(3):292-300. PubMed ID: 24576511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac safety assays.
    Heijman J; Voigt N; Carlsson LG; Dobrev D
    Curr Opin Pharmacol; 2014 Apr; 15():16-21. PubMed ID: 24721649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
    Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
    J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
    Schwartz PJ; Woosley RL
    J Am Coll Cardiol; 2016 Apr; 67(13):1639-1650. PubMed ID: 27150690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N; Authier S; Pugsley MK; Curtis MJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A history of the role of the hERG channel in cardiac risk assessment.
    Rampe D; Brown AM
    J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
    Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability.
    Pugsley MK; Hancox JC; Curtis MJ
    Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
    Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
    J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citalopram induced torsade de pointes, a rare life threatening side effect.
    Kanjanauthai S; Kanluen T; Chareonthaitawee P
    Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
    Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
    Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.